Skip to Content

Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review

NEW ORLEANS and CARLSBAD, Calif., November 06, 2008/PRNewswire-FirstCall/ Isis Pharmaceuticals, Inc. announces the following webcast:



    What:       Isis' cardiovascular program review of development and
                late-stage research candidates, including presentations

                -- Dr. Erik Stroes reporting top line data from an ongoing
                   Phase 2 mipomersen liver imaging study
                -- Dr. Evan Stein providing an update on an open-label
                   extension study of mipomersen in subjects with familial

    When:       Monday, November 10, 2008, at 6:00 p.m. CT (4:00 p.m.
                PT/7:00 p.m. ET)


    How:        Live on the Internet.  Simply log onto the website listed

    Contacts:   Kristina Lemonidis
                Associate Director, Corporate Development
                Isis Pharmaceuticals, Inc.
                (760) 603-2490

                Amy Blackley, Ph.D.
                Manager, Corporate Communications
                Isis Pharmaceuticals, Inc.
                (760) 603-2772


If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at



Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at

CONTACT: Kristina Lemonidis, Associate Director, Corporate Development,+1-760-603-2490, or Amy Blackley, Ph.D., Manager, Corporate Communications,+1-760-603-2772, both of Isis Pharmaceuticals, Inc.

Web site:

Ticker Symbol: (NASDAQ-NMS:ISIS)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: November 2008

View comments